Tomasini B R, Owen M C, Fenton J W, Mosher D F
Department of Medicine, University of Wisconsin, Madison 53706.
Biochemistry. 1989 Sep 19;28(19):7617-23. doi: 10.1021/bi00445a017.
We previously showed that the alpha-thrombin-antithrombin III complex causes antigenic change in vitronectin as monitored by the monoclonal anti-vitronectin antibody 8E6 (Tomasini & Mosher, 1988). We have extended these studies to other protease-serpin complexes and to gamma-thrombin, a proteolytic derivative of alpha-thrombin. In the presence of heparin, recognition of vitronectin by 8E6 was increased 64- or 52-fold by interaction with the complex of alpha-thrombin and heparin cofactor II or the Pittsburgh mutant (Met358----Arg) of alpha 1-protease inhibitor, respectively. This was comparable to the value obtained with the alpha-thrombin-antithrombin III complex. Factor Xa-serpin complexes were approximately 4-fold less effective than the corresponding thrombin complexes. alpha-Thrombin-serpin complexes but not Xa-serpin complexes formed disulfide-bonded complexes with vitronectin. Antigenic changes and disulfide-bonded complexes were not detected when trypsin- or chymotrypsin-serpin complexes were incubated with vitronectin. gamma-Thrombin caused 7- and 34-fold increases in recognition of vitronectin by MaVN 8E6 in the absence and presence of heparin, respectively. In contrast, alpha-thrombin by itself had no effect. The antigenic change induced by gamma-thrombin was maximal when gamma-thrombin and vitronectin were equimolar, was not dependent on cleavage of vitronectin, and was abolished by inhibition of gamma-thrombin with Phe-Pro-Arg-chloromethyl ketone but not with diisopropyl fluorophosphate. These data indicate that alpha-thrombin is the component in alpha-thrombin-serpin complexes that induces the antigenic change in vitronectin, probably via a region that is preferentially exposed in gamma-thrombin.
我们之前的研究表明,如通过单克隆抗玻连蛋白抗体8E6监测(托马西尼和莫舍,1988年),α-凝血酶-抗凝血酶III复合物会导致玻连蛋白发生抗原性变化。我们已将这些研究扩展至其他蛋白酶-丝氨酸蛋白酶抑制剂复合物以及γ-凝血酶(α-凝血酶的一种蛋白水解衍生物)。在肝素存在的情况下,8E6对玻连蛋白的识别分别因与α-凝血酶和肝素辅因子II的复合物或α1-蛋白酶抑制剂的匹兹堡突变体(Met358→Arg)相互作用而增加了64倍或52倍。这与α-凝血酶-抗凝血酶III复合物所获得的值相当。凝血因子Xa-丝氨酸蛋白酶抑制剂复合物的效力比相应的凝血酶复合物低约4倍。α-凝血酶-丝氨酸蛋白酶抑制剂复合物而非Xa-丝氨酸蛋白酶抑制剂复合物与玻连蛋白形成了二硫键结合的复合物。当胰蛋白酶-或糜蛋白酶-丝氨酸蛋白酶抑制剂复合物与玻连蛋白一起孵育时,未检测到抗原性变化和二硫键结合的复合物。在不存在和存在肝素的情况下,γ-凝血酶分别使MaVN 8E6对玻连蛋白的识别增加了7倍和34倍。相比之下,α-凝血酶本身没有作用。当γ-凝血酶和玻连蛋白等摩尔时,γ-凝血酶诱导的抗原性变化最大,不依赖于玻连蛋白的裂解,并且通过苯丙氨酸-脯氨酸-精氨酸-氯甲基酮抑制γ-凝血酶可消除该变化,但二异丙基氟磷酸不能消除。这些数据表明,α-凝血酶是α-凝血酶-丝氨酸蛋白酶抑制剂复合物中诱导玻连蛋白抗原性变化的成分,可能是通过γ-凝血酶中优先暴露的区域来实现的。